Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

In this study, the researchers found that after initial hair regrowth with ritlecitinib in patients with severe alopecia areata, it took a median of 93 days to reach clinical trial-defined scalp hair regrowth, with those responding earlier showing faster progression to desired outcomes.

In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.

This study found that topical calcipotriol lotion resulted in hair regrowth in 59.1% of alopecia areata patients, with better response observed in those with lower serum vitamin D levels.

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

This study evaluated the use of JAK inhibitors in patients with alopecia areata episodes lasting at least eight years and found that while the overall therapeutic response was limited, a subset of patients achieved meaningful hair regrowth, suggesting these treatments as a viable option.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

In this study, researchers found that patients with severe alopecia areata who respond to baricitinib treatment within six months may improve clinically within a year, while those with very severe disease may require at least a year for evidence of treatment effect.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

This study found that only a small percentage of alopecia areata patients treated with baricitinib in real-world settings would have met the eligibility criteria used in clinical trials.

In a retrospective multicenter cohort study, this research observed that baricitinib was effective and well-tolerated in treating adult patients with alopecia areata, including those with severe cases, showing promise in improving outcomes over a 12-month period with manageable side effects.

In this study, traditional treatment for pediatric alopecia areata was highly effective, with all patients achieving full hair regrowth. Tofacitinib and microneedling were less effective but are viable options for severe cases, while adverse effects were mild across all treatments.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

In this analysis, JAK inhibitors were found to provide clinically meaningful and durable hair regrowth in pediatric alopecia areata, outperforming traditional therapies with a manageable safety profile.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study observed that in a real-world pediatric setting, Janus kinase inhibitors led to improvements in scalp, eyebrow, and eyelash involvement in children with alopecia areata, with a generally favorable tolerability profile, though baseline imbalances and non-randomized treatment allocation limit causal conclusions and drug comparisons.